INNOVATIVELY DESIGNED TO SUPPORT ACTIVE UROTHELIAL REPAIR

Controcyst’s intelligent formulation combines established chondroitin sulphate with purified colostrum. While chondroitin sulphate helps rebuild a critical component of the GAG layer, the colostrum’s bioactive compounds are thought to tackle a root cause of bladder pain and support the bladder’s own natural capacity to heal.^1-4

Controcyst is indicated for the relief of painful symptoms associated with forms of chronic inflammation of the urothelium, such as BPS/IC and pelvic pain syndrome, including when induced by radio or chemotherapy¹.

Controcyst is a colostrum-enriched GAG therapy designed to support natural tissue repair^1–4

Rebuilds

Established chondroitin sulphate provides a key building block needed to help restore the dysfunctional GAG layer⁴

Regenerates

Purified colostrum provides the bioactive compounds to facilitate natural urothelial repair^1-3

Colostrum is a rich natural source of bioactive compounds that may support urothelial repair. ^2-3,5-7

Hover over or click the icons below to learn more about the bioactive compounds in purified colostrum.

Immune factors

that may dampen down persistent local inflammation

Glycoproteins

(lactoferrin and lactoperoxidase)
to help protect against pathogens and toxins

Growth factors

thought to stimulate active tissue regeneration

Controcyst has been shown to be clinically non-inferior* to iAluRil^® for pain and LUTS scores, offering meaningful relief for patients with BPS/IC^8,9

8x weekly instillations of Controcyst were compared to iAluRil^® (sodium hyaluronate, sodium chondroitin sulphate and calcium chloride) Prefill^® in two randomised, prospective, interventional, non-inferiority pilot studies in women with BPS (N=40 and N=24).

Improvement in quality of life (QoL), as measured by the IPSS for QoL, were comparable between Controcyst and iAluRil^® for both studies.^8,9

Controcyst’s formula is engineered to ease administration and support coating of the bladder wall¹

Controcyst is instilled into the bladder using an intermittent catheter and is recommended as a once-weekly instillation:¹

For BPS/IC

For Bladder Pain Syndrome (BPS) and Interstitial Cystitis (IC), clinical studies support once weekly instillations for 8 weeks (with results shown to be maintained at 3 and 6 month follow-ups).^8,9

For pain relief associated with rUTIs and other forms of chronic inflammation of the urothelium

It is recommended to perform once weekly instillations for 4 weeks, with subsequent management guided by clinical judgement.¹

Patient support resources

The Bladder Matters community: a supportive space for people living with bladder conditions

Patients will find:

Useful lifestyle tips
Real stories and experiences
Insights into bladder health and research
A space to connect and share experiences

Find us on Instagram and Facebook

Find out more about Controcyst

Do you have any questions about Controcyst? To find out more, speak with one of our Key Account Managers for you locality.

Speak to a member of the team

BPS=bladder pain syndrome; GAG=glycosaminoglycan; IC=interstitial cystitis; IPSS=International Prostatic Symptoms Score; LUTS=lower urinary tract symptoms; QoL=quality of life; rUTI=recurrent urinary tract infection; VAS=Visual Analogue Scale.

* Non-inferiority defined as a reduction in VAS for pain, and in IPSS score for LUTS, in the Controcyst groups that were at least 80% of the reduction observed in the iAluRil^® group. In the 2026 BPS study (N=40), Controcyst was non-inferior to iAluRil^® for mean VAS for pain reduction (Controcyst: -37.9% [4.75-2.95]; p=0.01 vs iAluRil^® -37.8% [4.9-3.05]; p=0.01). In the 2025 BPS study (N=24), Controcyst was non-inferior to iAluRil^® for mean IPSS (LUTS) decrease (Controcyst: -24.02% [15.69–11.92]; p=0.04 vs iAluRil^® -23.52% [18.3–14.0]; p=0.03)^8,9.

References

Controcyst IFU
Playford RJ & Weiser MJ. Nutrients. 2021;13(1):265
dos Santos PR, et al. Cell Biochem Funct. 2024;42:e4021
Wyndaele JJ., et al. Neurourology and Urodynamics. 2019;38:535–544
Rosa L, et al. Biochem Cell Biol. 2024;102(6):506-514
Ulfman LH., et al. Front Nutr. 2018;22(5):522
Conte AL, et al. Biometals. 2023;36:491-507
Controcyst DOF – REF-00329
Fanara F, et al. Continence. 2025;Abstract 101855

MAT-UK-CON-0029-2 | July 2026